Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)

Trial Profile

A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
  • Indications Alveolar soft part sarcoma; Chondrosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2019 Planned End Date changed from 1 Sep 2019 to 1 Apr 2020.
    • 04 Jan 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Apr 2020.
    • 06 Jun 2018 Planned number of patients changed from 60 to 100.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top